LEWISTON, N.Y., April 12 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC BB: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today that it earned record revenues, exceeding $200,000, in the first quarter of fiscal 2005.
Mr. Joseph T. Slechta, President and Chief Executive Officer of LAM, stated, "As we have reported to the shareholders, our Gel is being well received in Central America and China. We are pleased with the initial progress of commercial sales in these regions and look forward to continuing to grow our revenues in the coming months."
Mr. Slechta concluded, "Together with our partners, we are advancing our applications for clearance to market our product in several additional countries and expect to be able to announce exciting developments in the near future."
About LAM Pharmaceutical, Corp.
L.A.M. Pharmaceutical, Corp., http://www.lampharm.com/, is a biomedical company with offices in Lewiston, New York, Toronto, Canada and Beijing, China. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original L.A.M. Ionic Polymer Matrix(TM) technology (L.A.M. IPM(TM)), a proprietary and patented combination (a total of 15 U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. L.A.M. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.
L.A.M. Ionic Polymer Matrix(TM), L.A.M. IPM(TM) and IPM Wound Gel(TM) are trademarks of L.A.M. Pharmaceutical, Corp.
L.A.M. IPM Wound Gel(TM) is protected by one or more of the following patents: 5,897,880; 6,120,804; 6,007,843; 6,063,405.
Contact: Stephanie Carrington of The Ruth Group, 646-536-7017, for LAM Pharmaceutical, Corp.
LAM Pharmaceutical, Corp.